Effect of rosemary leaf powder with weight loss diet on lipid profile, glycemic status, and liver enzymes in patients with nonalcoholic fatty liver disease: A randomized, double-blind clinical trial.
Shayan AkbariMohammad Hassan SohouliSaeedeh EbrahimzadehFariborz Mansour GhanaeiAgha Fatemeh HosseiniNaheed AryaeianPublished in: Phytotherapy research : PTR (2022)
Experimental and some clinical studies have shown beneficial effects of rosemary leaf on liver function and biochemical parameters. The present study aimed to examine the impact of rosemary leaf powder with a weight loss diet in patients with nonalcoholic fatty liver disease. In a randomized double-blinded clinical trial, 110 patients were randomly assigned to receive either 4 g rosemary leaf or placebo (starch) powders for 8 weeks. In addition, all participants in the study were given weight loss diet and physical activity recommendations. Compared with baseline, alanine aminotransferase (p < .001), aspartate aminotransferase (p < .001), alkaline phosphatase (p < .001), gamma glutamyltransferase (p < .001), fasting blood glucose (p < .001), fasting insulin (p < .001), insulin resistance (p < .001), total cholesterol (p = .003), triglyceride (p < .001), low-density lipoprotein cholesterol (p < .001), and anthropometric indices (weight, body mass index, and waist circumferences) decreased significantly in the rosemary and placebo group with weight loss. However, after 8 weeks, no significant difference between the rosemary and placebo groups was detected in the variables as mentioned above except homeostasis model assessment of β-cell dysfunction (p = .014). The findings of the current clinical trial study revealed that rosemary group did produce changes, but they were not statistically different from those produced by the diet/activity intervention alone.
Keyphrases
- weight loss
- clinical trial
- bariatric surgery
- blood glucose
- physical activity
- double blind
- glycemic control
- roux en y gastric bypass
- gastric bypass
- insulin resistance
- phase iii
- body mass index
- study protocol
- open label
- single cell
- end stage renal disease
- weight gain
- stem cells
- ejection fraction
- adipose tissue
- metabolic syndrome
- depressive symptoms
- blood pressure
- body composition
- phase ii
- peritoneal dialysis
- bone marrow
- sleep quality
- low density lipoprotein
- clinical practice